Table 3.
Open in new tab

Change in serum biomarkers from baseline to 12-week follow-up.

Exercise n = 28Control n = 16p value
Change in IL-6, pg/ml−0.1 (−0.6, 0.6)0.3 (−0.1, 0.9)0.18
Change in TNF-alpha, pg/ml0.0 (−0.6, 0.5)0.2 (−0.3, 0.5)0.50
Change in galectin-3, pg/ml−0.5 (2.0)−0.8 (2.1)0.69
Exercise n = 28Control n = 16p value
Change in IL-6, pg/ml−0.1 (−0.6, 0.6)0.3 (−0.1, 0.9)0.18
Change in TNF-alpha, pg/ml0.0 (−0.6, 0.5)0.2 (−0.3, 0.5)0.50
Change in galectin-3, pg/ml−0.5 (2.0)−0.8 (2.1)0.69

Data are presented as mean (SD) or median (25th percentile, 75th percentile).

IL-6: interleukin-6; TNF-alpha: tumor necrosis factor alpha

Table 3.
Open in new tab

Change in serum biomarkers from baseline to 12-week follow-up.

Exercise n = 28Control n = 16p value
Change in IL-6, pg/ml−0.1 (−0.6, 0.6)0.3 (−0.1, 0.9)0.18
Change in TNF-alpha, pg/ml0.0 (−0.6, 0.5)0.2 (−0.3, 0.5)0.50
Change in galectin-3, pg/ml−0.5 (2.0)−0.8 (2.1)0.69
Exercise n = 28Control n = 16p value
Change in IL-6, pg/ml−0.1 (−0.6, 0.6)0.3 (−0.1, 0.9)0.18
Change in TNF-alpha, pg/ml0.0 (−0.6, 0.5)0.2 (−0.3, 0.5)0.50
Change in galectin-3, pg/ml−0.5 (2.0)−0.8 (2.1)0.69

Data are presented as mean (SD) or median (25th percentile, 75th percentile).

IL-6: interleukin-6; TNF-alpha: tumor necrosis factor alpha

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close